vTv Therapeutics Inc. (NASDAQ: VTVT) stock jumped 12.22% on Friday to $1.01 against a previous-day closing price of $0.90. With 1.0 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.93 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.0500 whereas the lowest price it dropped to was $0.8801. The 52-week range on VTVT shows that it touched its highest point at $2.17 and its lowest point at $0.38 during that stretch. It currently has a 1-year price target of $4.17. Beta for the stock currently stands at -1.43.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VTVT was up-trending over the past week, with a rise of 33.86%, but this was up by 34.67% over a month. Three-month performance surged to 46.33% while six-month performance rose 40.28%. The stock lost -47.40% in the past year, while it has gained 1.51% so far this year. A look at the trailing 12-month EPS for VTVT yields -0.24 with Next year EPS estimates of -0.38. For the next quarter, that number is -0.09. This implies an EPS growth rate of -18.60% for this year and -45.20% for next year.
Float and Shares Shorts:
At present, 66.94 million VTVT shares are outstanding with a float of 30.33 million shares on hand for trading. On Apr 28, 2022, short shares totaled 1.75 million, which was 1.94% higher than short shares on Mar 30, 2022. In addition to Mr. Richard S. Nelson as the firm’s Interim CEO & Director, Mr. Barry Brown serves as its Chief Accounting Officer.
Through their ownership of 9.47% of VTVT’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 92.10% of VTVT, in contrast to 3.17% held by mutual funds. Shares owned by individuals account for 2.15%. As the largest shareholder in VTVT with 2.61% of the stake, The Vanguard Group, Inc. holds 1,749,876 shares worth 1,749,876. A second-largest stockholder of VTVT, Ikarian Capital LLC, holds 742,980 shares, controlling over 1.11% of the firm’s shares. Geode Capital Management LLC is the third largest shareholder in VTVT, holding 347,567 shares or 0.52% stake. With a 1.23% stake in VTVT, the Vanguard Explorer Fund is the largest stakeholder. A total of 820,390 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 0.93% of VTVT stock, is the second-largest Mutual Fund holder. It holds 625,032 shares valued at 0.47 million. Vanguard Extended Market Index Fu holds 0.46% of the stake in VTVT, owning 304,454 shares worth 0.23 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VTVT since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With VTVT analysts setting a high price target of $5.00 and a low target of $1.50, the average target price over the next 12 months is $3.25. Based on these targets, VTVT could surge 395.05% to reach the target high and rise by 48.51% to reach the target low. Reaching the average price target will result in a growth of 221.78% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. VTVT will report FY 2022 earnings on 03/01/2023. Analysts have provided yearly estimates in a range of -$0.26 being high and -$0.47 being low. For VTVT, this leads to a yearly average estimate of -$0.36. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. vTv Therapeutics Inc. surprised analysts by -$0.03 when it reported -$0.10 EPS against a consensus estimate of -$0.07. The surprise factor in the prior quarter was -$0.02. Based on analyst estimates, the high estimate for the next quarter is -$0.08 and the low estimate is -$0.10. The average estimate for the next quarter is thus -$0.09.
Summary of Insider Activity:
Insiders traded VTVT stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has risen to 1 over the past year. The total number of shares bought during that period was 0 while 87,000 shares were sold.